Please login to the form below

Not currently logged in
Email:
Password:

BMS-986205

This page shows the latest BMS-986205 news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Bristol-Myers Squibb hammered another nail in the coffin of IDO1 as a drug target in immuno-oncology yesterday after halting two trials of its BMS-986205 candidate acquired

Latest news

  • BMS boosts immuno-oncology with $2.3bn IFM buy BMS boosts immuno-oncology with $2.3bn IFM buy

    The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and LAG-3 (BMS-986016) - all in phase ... Adding the new candidates "broadens our ability to investigate

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics